ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Invests In Discovery Start-Ups

by Rick Mullin
January 18, 2016 | APPEARED IN VOLUME 94, ISSUE 3

Pfizer has made equity investments totaling $46 million in four early-stage drug discovery companies in a program through which the firms will have access to Pfizer’s R&D resources. Pfizer is investing in BioAtla, which is developing monoclonal antibodies called conditionally active biologics as oncology therapies; NextCure, a firm that Pfizer helped form and is focused on immuno-oncology; Cortexyme, specializing in treatments that alter the course of neurodegenerative diseases; and 4D Molecular Therapeutics, a new biopharmaceutical company with its eye on gene therapy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment